^
    Back
    Association details:
    Biomarker:NRAS mutation
    Cancer:Melanoma
    Drug:LY3009120 (pan-RAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Cancer Cell
    Title:

    Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers

    Excerpt:
    Consequently, LY3009120 induces minimal paradoxical activation, inhibits MEK phosphorylation, and exhibits anti-tumor activities in vitro and in vivo in cancer models carrying oncogenic KRAS, NRAS, or BRAF mutations....Table 1Anti-proliferation Activities of LY3009120, Vemurafenib, and Selumetinib in Melanoma Cells in Soft Agar Assays
    DOI:
    https://doi.org/10.1016/j.ccell.2015.08.002